Join the Gemtesa group to help and get support from people like you.
Gemtesa News
FDA Approves Gemtesa for Overactive Bladder in Men With BPH
THURSDAY, Jan. 2, 2025 – Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy for benign...
Sumitomo Pharma America Announces U.S. FDA Approval of Gemtesa (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
MARLBOROUGH, Mass., Dec. 23, 2024 /PRNewswire/ – Sumitomo Pharma America, Inc. (SMPA) announced today that the U.S. Food and Drug Administration (FDA) has approved Gemtesa (vibegron), a beta-3 (β3) ...
FDA Approves Gemtesa (vibegron) Tablets for the Treatment of Patients with Overactive Bladder (OAB)
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dec. 23, 2020-- Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug...